PKCɛ is targeted by miR-205 in prostate cancer [63], miR-107 in head and neck squamous cell carcinoma [64], miR-31 in breast cancer [65], miR-143 in lung cancer [66] and miR-146a in papillary thyroid cancers [67]. Here, PRRT2 is linked to head and neck squamous cell carcinoma.